

No. 6613304, filed September 16, 2015 and entitled “Anti-CD276 Polypeptides and Proteins” [HHS Reference No. E-250-2014-0-JP-05]; Japanese Patent No. 6734227, filed May 25, 2017 and entitled “Anti-CD276 Polypeptides and Proteins” [HHS Reference No. E-250-2014-JP-07]; European Patent No. 3193933, filed September 16, 2015 and entitled “Anti-CD276 Polypeptides and Proteins” [HHS Reference No. E-250-2014-0-EP-06] and as validated in Germany, Spain, France, UK, and Italy; and US Patent Application No. 16/812,980, filed March 9, 2020 [HHS Reference No. E-250-2014-0-US-08]; and

United States Provisional Patent Application 62/947,135, filed December 12, 2019, and entitled “ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF” [HHS Reference No. E-145-2019-0-US-01]; PCT Application No. PCT/US2020/063732, filed December 8, 2020, and entitled “ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF” [HHS Reference No. E-145-2019-0-PCT-02]; Australian Application No. 2020402752, filed December 8, 2020, and entitled “ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF” [HHS Reference No. E-145-2019-0-AU-03]; Canadian Application No. 3161573, filed December 8, 2020, and entitled “ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF” [HHS Reference No. E-145-2019-0-CA-04]; European Application No. 20834060.4, filed December 8, 2020, and entitled “ANTIBODY-DRUG CONJUGATES SPECIFIC FOR CD276 AND USES THEREOF” [HHS Reference No. E-145-2019-0-EP-05]; Japanese Application No. 2022-535127, filed December 8, 2020 [HHS Reference No. E-145-2019-0-JP-06]; US Patent Application No. 17/783,171, filed June 7, 2022 [HHS Reference No. E-145-2019-0-US-07]; and all U.S. and foreign patent applications claiming priority to the aforementioned applications for each technology.

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be worldwide and the field of use may be limited to: “The use, development, manufacturing and commercialization of an antibody-drug conjugate (ADC) with single antigen specificity comprising:

(1) The CDR sequences of the m8524/m276 monoclonal antibody;

(2) a cleavable or non-cleavable linker; and

(3) a payload selected from the following categories: pyrrolobenzodiazepine (PBD), maytansinoid, auristatin, camptothecin, TLR agonist, STING agonist, cytokine or cytokine mimetic, targeted protein degrader, or oligonucleotide; for the treatment of CD276-expressing solid tumors.

The licensed field of use specifically excludes any (a) non-specified immunoconjugates, including, but not limited to, chimeric antigen receptors (CARs) and variants thereof, (b) unconjugated antibodies, (c) bispecific antibodies, and (d) antibody-radioligand conjugates.”

CD276, also known as B7-H3, is a cell surface tumor endothelial marker that is highly expressed in the tumor vessels of human lung, breast, colon, endometrial, renal, and ovarian cancer, but not in the angiogenic vessels of healthy tissue. This differential expression makes CD276 an attractive target for cancer treatment due to the ability to selectively target pathological angiogenesis without impacting physiological angiogenesis. The E-250-2014 technology discloses antibodies that bind selectively to CD276 and other antibody-based therapeutic formats such as antibody drug conjugates (ADCs). The E-145-2019 technology discloses an ADC based on a modified version of the m276/m8524 antibody that is disclosed under E-250-2014 that incorporates mutations for site-directed conjugation and disruption of Fc receptor binding.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: February 27, 2023.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2023-04411 Filed 3-2-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Complementary & Integrative Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Complementary and Integrative Health Special Emphasis Panel; HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain and Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement.

Date: March 21, 2023.

Time: 1:30 p.m. to 5:00 p.m.

Agenda: To review and evaluate cooperative agreement applications.

Place: National Center for Complementary and Integrative, Democracy II, 6707 Democracy Blvd., Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Sushmita Purkayastha, Ph.D., Scientific Review Officer, Office of Scientific Review, Division of Extramural Activities, NCCIH/NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20892-5475, sushmita.purkayastha@nih.gov.

Sonia Elena Nanesco, Ph.D., Scientific Review Officer, Office of Scientific Review, Division of Extramural Activities, NCCIH/NIH, 6707 Democracy Boulevard, Suite 401, Bethesda, MD 20817, Sonia.nanesco@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS)

Dated: February 28, 2023.

Victoria E. Townsend,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-04408 Filed 3-2-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Catalyze Product Definition.

Date: April 5, 2023.

Time: 10:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Dr, Bethesda, MD 20841 (Virtual Meeting).

Contact Person: Kristin Goltry, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 209-B, Bethesda, MD 20892, (301) 435-0297, goltrykl@mail.nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; R13 Conference Grant Review.

Date: April 6, 2023.

Time: 10:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).

Contact Person: Tony L. Creazzo, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 207-Q, Bethesda, MD 20892-7924, (301) 827-7913, creazzotl@mail.nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Catalyze Enabling Technologies.

Date: April 7, 2023.

Time: 11:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Dr, Bethesda, MD 20817 (Virtual Meeting).

Contact Person: Kristin Goltry, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 209-B, Bethesda, MD 20892, (301) 435-0297, goltrykl@mail.nih.gov.

Name of Committee: National Heart, Lung, and Blood Institute Special Emphasis Panel; Red Cell Alloimmunization.

Date: April 17, 2023.

Time: 1:00 p.m. to 4:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Rockledge I, 6705 Rockledge Dr, Bethesda, MD 20817 (Telephone Conference Call).

Contact Person: Michael P. Reilly, Ph.D., Scientific Review Officer, Office of Scientific Review/DERA, National Heart, Lung, and Blood Institute, National Institutes of Health, 6705 Rockledge Drive, Room 208-Z, Bethesda, MD 20892, (301) 827-7975, reillymp@nhlbi.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS)

Dated: February 27, 2023.

David W. Freeman,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-04362 Filed 3-2-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Eunice Kennedy Shriver National Institute of Child Health and Human Development; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Special Emphasis Panel, March 29, 2023, 9:30 a.m. to March 29, 2023, 6 p.m., Eunice Kennedy Shriver National Institute of Child Health and Human Development, Scientific Review Branch, 6710 B Rockledge Drive, Bethesda, MD, 20817 which was published in the **Federal Register** on February 13, 2023, FR Doc 2023-02980, 88 FR 9299.

This notice is being amended to replace the listed contact person. Dr. Luis Dettin will replace Dr. Cathy Wedeen. The meeting is closed to the public.

Dated: February 27, 2023.

David W. Freeman,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-04361 Filed 3-2-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HOMELAND SECURITY

U.S. Customs and Border Protection

[1651-0009]

Customs Declaration (CBP Form 6059B)

AGENCY: U.S. Customs and Border Protection (CBP), Department of Homeland Security.

ACTION: 60-Day notice and request for comments; revision of an existing collection of information.

SUMMARY: The Department of Homeland Security, U.S. Customs and Border Protection will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The information collection is published in the **Federal Register** to obtain comments from the public and affected agencies.

DATES: Comments are encouraged and must be submitted (no later than May 2, 2023) to be assured of consideration.

ADDRESSES: Written comments and/or suggestions regarding the item(s) contained in this notice must include the OMB Control Number 1651-0009 in the subject line and the agency name. Please use the following method to submit comments:

Email: Submit comments to: CBP_PRA@cbp.dhs.gov.

Due to COVID-19-related restrictions, CBP has temporarily suspended its ability to receive public comments by mail.

FOR FURTHER INFORMATION CONTACT:

Requests for additional PRA information should be directed to Seth Renkema, Chief, Economic Impact Analysis Branch, U.S. Customs and Border Protection, Office of Trade, Regulations and Rulings, 90 K Street NE, 10th Floor, Washington, DC 20229-1177, Telephone number 202-325-0056 or via email CBP_PRA@cbp.dhs.gov. Please note that the contact information provided here is solely for questions regarding this notice. Individuals seeking information about other CBP programs should contact the CBP National Customer Service Center at 877-227-5511, (TTY) 1-800-877-8339,